NGEN
NervGen Pharma Corp. Common stock
There isn't enough reported data to score NGEN yet.
NGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NGEN's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NGEN PE Valuation
NGEN has no meaningful PE right now: it lost money over the past year.
NGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect NGEN's losses to grow, with revenue holding steady.
NGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.60 | -$0.33 |
| Q1 2026 | -$0.46 | -$0.21 |
| Q4 2025 | -$0.48 | -$0.24 |
| Q3 2025 | -$0.25 | +$0.01 |
| Q2 2025 | -$0.27 | -$0.01 |
| Q1 2025 | -$0.25 | -$0.01 |
| Q4 2024 | -$0.24 | +$0.03 |
| Q3 2024 | -$0.26 | -$0.03 |
NGEN lost $0.60 per share over the past year, a bigger loss than the year before.
NGEN Quarterly Revenue
NGEN's revenue is shrinking: $0 last quarter.
NGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.1M | -$1.5M |
| Q1 2026 | -$5.9M | -$3M |
| Q4 2025 | -$7.1M | -$4.5M |
| Q3 2025 | -$3.7M | +$294.2K |
| Q2 2025 | -$2.6M | +$347.8K |
| Q1 2025 | -$2.9M | -$592K |
| Q4 2024 | -$2.6M | -$401.3K |
| Q3 2024 | -$4M | -$3M |
NGEN has burned cash in almost every quarter: −$21M over the past year, against −$12M the year before.
NGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +12.5M shares |
| 1 year | +28% | +20.5M shares |
| 3 years | +56% | +33.2M shares |
| 5 years | +146% | +54.8M shares |
| Available history | +232% | +64.6M shares |
NGEN has 92M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NGEN hasn't bought back shares in the past year.
NGEN Net Leverage
NGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 12.5 | Oversold |
NGEN's weekly RSI is 37 (neutral) and its Stochastic is 13 (oversold).
NGEN PE vs Healthcare Sector
NGEN has no meaningful PE right now: it lost money over the past year.
NGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.60 | 1.9% above |
| 20 week MA | $1.79 | 8.9% below |
NGEN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 8.9% below its 20-week average.
NGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $5.88 | $1.63 | -72% |
It's down 72% so far in 2026.